AURA — AURA BIOSCIENCES Income Statement
0.000.00%
Last trade - 00:00
- $357.42m
- $131.27m
- 29
- 29
- 54
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 24.1 | 22.2 | 35.3 | 60.3 | 85 |
Operating Profit | -24.1 | -22.2 | -35.3 | -60.3 | -85 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -24.2 | -22.2 | -35.3 | -58.8 | -76.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.2 | -22.2 | -35.3 | -58.8 | -76.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -24.2 | -22.2 | -35.3 | -58.8 | -76.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.2 | -30.1 | -46.2 | -58.8 | -76.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.06 | -1.06 | -1.58 | -1.95 | -1.93 |